Back to Search Start Over

Monoclonal antibody-navigated carbon-encapsulated iron nanoparticles used for MRI-based tracking integrin receptors in murine melanoma.

Authors :
Bamburowicz-Klimkowska M
Bystrzejewski M
Kasprzak A
Cieszanowski A
Grudzinski IP
Source :
Nanomedicine : nanotechnology, biology, and medicine [Nanomedicine] 2024 Jan; Vol. 55, pp. 102721. Date of Electronic Publication: 2023 Nov 24.
Publication Year :
2024

Abstract

Integrin beta-3 is a cell adhesion molecule that mediate cell-to-cell and cell-to-extracellular matrix communication. The major goal of this study was to explore melanoma cells (B16F10) based upon specific direct targeting of the β3 subunit (CD61) in the integrin αvβ3 receptor using carbon-encapsulated iron nanoparticles decorated with monoclonal antibodies (Fe@C-CONH-anti-CD61 and Fe@C-(CH <subscript>2</subscript> ) <subscript>2</subscript> -CONH-anti-CD61). Both melanoma cells treated with nanoparticles as well as C57BL/6 mice bearing syngeneic B16-F10 tumors intravenously injected with nanoparticles were tested in preclinical MRI studies. The as-synthesized carbon-encapsulated iron nanoparticles functionalized with CD61 monoclonal antibodies have been successfully used as a novel targeted contrast agent for MRI-based tracking melanoma cells expressing the β3 subunit of the integrin αvβ3 receptor.<br />Competing Interests: Declaration of competing interest The authors declare that there are no conflicts of interest.<br /> (Copyright © 2023 Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1549-9642
Volume :
55
Database :
MEDLINE
Journal :
Nanomedicine : nanotechnology, biology, and medicine
Publication Type :
Academic Journal
Accession number :
38007065
Full Text :
https://doi.org/10.1016/j.nano.2023.102721